Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Further US Lawsuit Claims Price-Fixing Conspiracy

Executive Summary

Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.

Advertisement

Related Content

Generics Save US Nearly $300bn In 2018 And $2tn Over A Decade
AAM's Davis Cautions Against 'Court Of Public Opinion' On Price-Fixing Claims
Teva Takes A Further Hit On Value Of Actavis
Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market
United Healthcare Targets Multiple Firms Over US Pricing
US Court Denies Attempt To Silence Leaks In Pricing Litigation
Leaks And Prejudice Must End In US Multi-State Pricing Case

Topics

Related Companies

What to read next

Advertisement
UsernamePublicRestriction

Register

GB140331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel